Abstract： Objective： To observe the clinical effect of the combination use of Huatan Huoxue prescription and VCD (Bortezomib+Dexamethasone+Cyclophosphamide) Plan on multiple myeloma and its effect on immune function and inflammatory factors. Methods：A total of 80 patients with multiple myeloma were selected as the study objects and were divided into the routine VCD group and the Chinese medicine combination group according to the random number table method， with 40 cases in each group. The routine VCD group was given VCD plan for chemotherapy， and the Chinese medicine combination group was additionally treated with Huatan Huoxue prescription based on the VCD plan. The clinical effects and incidence of adverse reactions， and the levels of immune function indexes [CD4+，CD8+ and NKT cell] and inflammatory factors [C-reactive protein (CRP) and tumor necrosis factor α (TNF- α)] before and after treatment were compared between the two groups. Results： The total effective rate was 95.00% in the Chinese medicine combination group and 77.50% in the routine VCD group， the difference being significant (P＜0.05). After treatment， the levels of CD4+ and NKT cell in the Chinese medicine combination group were higher than those before treatment and in the control group (P＜0.05)， and the CD8+ level was lower than that before treatment and in the control group (P＜0.05)； there was no significant difference being found in the comparisons of levels of CD4+， CD8+ and NKT cell in the routine VCD group before and after treatment (P＞0.05). After treatment， the levels of serum CRP and TNF- α in the two groups were decreased when compared with those before treatment (P＜0.05)， and the levels of serum CRP and TNF- α in the Chinese medicine combination group were lower than those in the routine VCD group (P＜ 0.05). During the treatment， the incidence of adverse reactions was 17.50% in the Chinese medicine combination group and 12.50% in the routine VCD group， there being no significance in the difference (P＞ 0.05). Conclusion：The combination use of Huatan Huoxue prescription and VCD plan for chemotherapy in can significantly improve the clinical effect on multiple myeloma， effectively regulate the immune function of patients and reduce the inflammatory responses of the body with no significant increase in adverse drug reactions.